Dendrimer entrapped microsponge gel of dithranol for effective topical treatment.
Materials science
Pharmaceutical science
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
07
08
2018
revised:
31
12
2018
accepted:
11
03
2019
entrez:
9
4
2019
pubmed:
9
4
2019
medline:
9
4
2019
Statut:
epublish
Résumé
Dithranol is one of the important topical agents for the treatment of psoriasis, a chronic inflammatory skin disease with aberrant differentiation of keratinocytes. However, its application is troublesome and inconvenient because of its associated side effects, including staining, burning sensation, irritation, and necrotizing effect on the diseased cells as well as on the normal cells. The purpose of the current investigation was to explore the potential of poly(amido) amine (PAMAM) dendrimers in the topical delivery of dithranol through a novel microsponge based gel. Generation-4 (G4) dendrimers were incorporated into the microsponge based gel formulation by quasi-emulsion solvent diffusion method with varying concentration of polymers, and evaluated for the morphology of the formulation, encapsulation efficiency and skin irritation potential. Percentage yield of the formulation was found to be 66.28%, whereas encapsulation efficiency was ranged between 71.33% to 49.21%, and an average particle size was ranged between 28 ± 1.12 μm to 130 ± 1.01 μm. Surface morphology of developed microsponge was confirmed by scanning electron microscopy, revealed micro-porous nature. The optimized microsponge formulation was found to be stable and recorded non-irritant during cutaneous application of the experimental animals. Further, the pharmacokinetic outcomes of study were showed prolong penetration of the drug through the skin, equivalent to the marketed formulation of dithranol. Therefore, it could be conferred that the microsponge formulation of the PAMAM entrapped dithranol can produce prolonged efficacy without producing toxicities to the skin, and thus can effectively be projected in the treatment of diseases like psoriasis.
Identifiants
pubmed: 30957038
doi: 10.1016/j.heliyon.2019.e01343
pii: S2405-8440(18)34413-X
pii: e01343
pmc: PMC6431737
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e01343Références
Diabetes Res Clin Pract. 2018 Feb;136:52-77
pubmed: 29196152
J Dtsch Dermatol Ges. 2012 Mar;10 Suppl 2:S1-95
pubmed: 22386073
Drug Test Anal. 2013 Jun;5(6):485-91
pubmed: 22374835
Skin Pharmacol. 1990;3(1):1-20
pubmed: 2202336
Int J Pharm. 2014 Jan 2;460(1-2):131-43
pubmed: 24239580
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:868-880
pubmed: 30033322
J Invest Dermatol. 2015 Dec;135(12):2955-2963
pubmed: 26214380
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963
pubmed: 28895202
Arch Dermatol. 2012 Jan;148(1):95-102
pubmed: 22250239
Drug Discov Today. 2017 Apr;22(4):652-664
pubmed: 28219742
FASEB J. 2005 Jun;19(8):1012-4
pubmed: 15802490
Colloids Surf B Biointerfaces. 2014 Mar 1;115:286-94
pubmed: 24388859
Indian Dermatol Online J. 2017 Jul-Aug;8(4):235-245
pubmed: 28761838
Curr Pharm Des. 2017;23(17):2504-2531
pubmed: 27908273
Rev Assoc Med Bras (1992). 2017 Sep;63(9):747-752
pubmed: 29239461
Clin Dermatol. 1997 Sep-Oct;15(5):723-37
pubmed: 9313971
J Pharm Sci. 2017 Jul;106(7):1736-1751
pubmed: 28412398
J Basic Clin Pharm. 2016 Mar;7(2):39-48
pubmed: 27057125
Saudi Pharm J. 2015 Oct;23(5):562-72
pubmed: 26594124
Mater Sci Eng C Mater Biol Appl. 2015 Jan;46:69-76
pubmed: 25491961
Ann R Coll Surg Engl. 1994 Jan;76(1):3-4
pubmed: 8117015